Andrew Spencer, MD, MBBS, FRACP, FRCPA, discusses the rationale to evaluate panobinostat in multiple myeloma.
Andrew Spencer, MD, MBBS, FRACP, FRCPA
Advertisement
Articles by Andrew Spencer, MD, MBBS, FRACP, FRCPA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5